Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19679351 | 0.88 | USP2 (0.43) | USP2SMN1; SMN2RIPK1ESR2NR1H2 | |
| SCHEMBL19667597 | 0.87 | USP2 (0.43) | USP2SMN1; SMN2RIPK1ESR2NR1H2 | |
| SCHEMBL19667151 | 0.86 | USP2 (0.44) | USP2SMN1; SMN2RIPK1ESR2NR1H2 | |
| SCHEMBL19667083 | 0.86 | ESR2 (0.44) | USP2SMN1; SMN2RIPK1ESR2NR1H2 | |
| SCHEMBL19667604 | 0.84 | USP2 (0.41) | USP2SMN1; SMN2RIPK1ESR2NR1H2 | |
| SCHEMBL19667456 | 0.83 | RIPK1 (0.44) | USP2SMN1; SMN2RIPK1ESR2NR1H2 | |
| SCHEMBL19684696 | 0.81 | RIPK1 (0.39) | USP2SMN1; SMN2RIPK1ESR2GPR119 | |
| SCHEMBL19667310 | 0.81 | USP2 (0.44) | USP2SMN1; SMN2ESR2NR1H2GPR119 | |
| SCHEMBL17462516 | 0.80 | ESR2 (0.45) | USP2SMN1; SMN2RIPK1ESR2NR1H2 | |
| SCHEMBL19667666 | 0.79 | ESR2 (0.56) | ESR2NR1H2MKNK1MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464249-B1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3464249-B1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2021-08-11 | — | — | EP | disclosed |
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-04-18 | — | — | US | disclosed |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-04-18 | — | — | US | disclosed |
| EP-3464249-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Inc (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | DUT, NCL, TYMP | USP2 3416/4885SMN1; SMN2 1375/4885RIPK1 3885/4885 |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | USP2 3416/4885SMN1; SMN2 1375/4885RIPK1 3885/4885 |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | USP2 3416/4885SMN1; SMN2 1375/4885RIPK1 3885/4885 |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | DUT, NCL, TYMP | USP2 3416/4885SMN1; SMN2 1375/4885RIPK1 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.